Research Shows CBG Destroys Gastrointestinal Cancer Cells

Numerous studies have concluded that gastrointestinal cancers are among the most widespread causes of cancer-related deaths worldwide

This is exactly why the Maryland-based Cannabics Pharmaceuticals Inc. conducted its own experiments involving two hemp extracts, cannabigerol (CBG) and cannabichromene (CBC), proving that they can, in fact, successfully destroy Gastrointestinal Cancer Cells (GCC) in humans.

Upon announcing the preliminary results of the study, Dr. Eyal Ballan, the co-founder and CTO  of Cannabics Pharmaceuticals Inc., stated that one of the company’s main aims was to personalize cancer treatments and that CBG may be the perfect way of doing just that.

Scientists tested CBD, CBG, and CBC, and discovered a connection between the cannabinoid’s Topological Polar Surface Area and their ability to activate anti-cancer activity and lower the survival rate of cancer cells; CBC and CBG showed considerably higher rates of anti-cancer activity than other cannabinoids.

Leave a Reply